Several COVID vaccines are approaching commercial launch in Japan, coinciding with an ongoing biosimilars boom
Japan has topped the global ‘API quality’ rankings, according to recent CPhI data. The country has also increased its ‘overall competitiveness’ score by 2%, and ranks a global third – behind USA and Germany – for its ‘finished product manufacturing’ quality and ‘innovativeness for solid dose’.
Several COVID vaccines are approaching commercial launch in Japan, coinciding with an ongoing biosimilars boom. Competition for partners and supply chain resources is increasing quickly, with more than 60% of Japanese companies stating potential partners are ‘approaching them much earlier than before’ CPhI data says.
Laura Murina, Brand Manager, Informa Markets, said: “Interest from international audiences about how to enter Japan and find regional suppliers and manufacturers remains extremely strong. Demand for generics in particular continues to grow, with companies looking for stable supply chains and alternative suppliers, which is why international interest in networking is so strong. In fact, alongside the matchmaking program, we have an international seminar program addressing the opportunities and challenges when looking to enter Asia’s second largest pharma market.
“What we have seen globally, and has been even more true in Japan, is that companies are looking at diversifying their supply chains and increasing resilience – naturally this means meeting and pre-auditing new partners.”
CPhI Japan 2022 is returning as a hybrid event, with a live exhibition at the Big Sight Exhibition Center, Tokyo in April, alongside an online networking platform, designed to replicate the onsite experience.
Online attendees, as well as exhibitors and visitors, can use the digital matchmaking system from March 15th, and online meetings are available to be held for the majority of April (from the 4th through until the 28th).